Skip to main content

Research Repository

Advanced Search

Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study (IRIS)

Lina, Bruno; Boucher, Charles; Osterhaus, Albert; Monto, Arnold S.; Schutten, Martin; Whitley, Richard J.; Nguyen-Van-Tam, Jonathan S.

Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study (IRIS) Thumbnail


Authors

Bruno Lina

Charles Boucher

Albert Osterhaus

Arnold S. Monto

Martin Schutten

Richard J. Whitley

Jonathan S. Nguyen-Van-Tam



Abstract

Background and Objectives: The Influenza Resistance Information Study (IRIS) was initiated in 2008 to study the emergence of neuraminidase inhibitor (NAI) resistance and the clinical course of influenza in immunocompetent treated and untreated patients.

Methods: Patients had throat/nose swabs collected on Days 1, 3, 6 and 10 for analyses of influenza type, subtype and virus susceptibility to NAIs. RT-PCR Positive samples were cultured, and tested for NAI resistance by specific RT-PCR and phenotypic testing. Scores for influenza symptoms were recorded on diary cards (Days 1–10). This study focuses on Influenza A infected cases only.

Results: Among 3230 RT-PCR-positive patients, 2316 had influenza A of whom 1216 received oseltamivir monotherapy within 2 days of symptom onset (9 seasonal H1N1; 662 H3N2; 545 H1N1pdm2009). Except for 9 patients with naturally resistant seasonal H1N1 (2008/9), no resistance was detected in Day 1 samples. Emergence of resistance (post-Day 1) was detected in 43/1207 (3.56%) oseltamivir-treated influenza A infected patients, with a higher frequency in 1 to 5-year-old (11.8%) versus >5-year-old (1.4%). All N1 and N2 resistant viruses had H275Y (n=27) or R292K (n=16) substitutions, respectively. For 43 patients, virus clearance was significantly delayed versus treated patients with susceptible viruses (8.1 vs 10.9 days; p<0.0001), and 11 (23.2%) remained RT-PCR positive for influenza at Day 10. However their symptoms resolved by Day 6 or earlier.

Conclusions: Oseltamivir resistance was only detected during antiviral treatment, with the highest incidence occurring among 1–5-year-olds. Resistance delayed viral clearance, but had no impact on symptom resolution.

Citation

Lina, B., Boucher, C., Osterhaus, A., Monto, A. S., Schutten, M., Whitley, R. J., & Nguyen-Van-Tam, J. S. (2018). Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study (IRIS). Influenza and Other Respiratory Viruses, 12(2), 267-278. https://doi.org/10.1111/irv.12534

Journal Article Type Article
Acceptance Date Nov 6, 2017
Online Publication Date Jan 15, 2018
Publication Date 2018-03
Deposit Date Nov 17, 2017
Publicly Available Date Jan 15, 2018
Journal Influenza and Other Respiratory Viruses
Print ISSN 1750-2640
Electronic ISSN 1750-2659
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 12
Issue 2
Pages 267-278
DOI https://doi.org/10.1111/irv.12534
Keywords antiviral; influenza; neuraminidase inhibitor; resistance
Public URL https://nottingham-repository.worktribe.com/output/904751
Publisher URL http://onlinelibrary.wiley.com/doi/10.1111/irv.12534/full
Contract Date Nov 17, 2017

Files





You might also like



Downloadable Citations